1Drahl C. Anticoagulants in the pipeline may overcome the drawbacks of well - entrenched drugs [ J ]. Chem Eng News, 2010,88(33) :15 -22.
2Turpie AG,Eriksson BI,lassen MR, et al, A meta - analysis of fondaparinux versus enoxaparin in the prevention of ve- nousthromboembolism after major orthopaedic surgery . [ J ] South Orthop Assoc, 2002,11 (4) : 182 - 188.
3Buller HR, Davidson BL, Decousus H, et, al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in theinitial treatment of pulmonary embolism. N Engl J Med, 2003,349 ( 18 ) : 1695 - 1702.
4Buller HR, Cohen AT, Davidson B, et al. Extended prophy- laxis of venous thromboembolism with idraparinux. N Engl J Med,2007,357 ( 11 ) : 1105 - 1112.
5Kibbitz D, Becka M,Wensing G,et al.Safety, pharmacodynamics, and pharma-cokinetics of BAY 59 - 7939 - anoral, direct factor Xa in- hibitor - after multiple dosing inhealthy male subjects [ J ]. Eur J Clin Pharmacol,2005,61 (12) :873.
6Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynam- ics, and pharmacokinetics of single doses of BAY59 - 7939, an oral, direct factor Xa inhibitor [ J ]. Clin Pharmacol Ther,2005,78(4) :412.
7Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med,2012,366(14) : 1287 - 1297.
2Okubo K, Uchida E, Nogami S, et al. Levocabastine nasal spray significantly improves perennial allergic rhinitis : a single-blind placebo-controlled study[J]. Auris Nasus Larynx,2010,37(4) :436-442.
3Bates SM, Weitz JI. The status of new anticoagulants[ J]. Br J Haematol,2006,134 ( 1 ) :3-19.
4Drahl C. Anticoagulants in the pipeline may overcome the drawbacks of well-entrenched drugs [ J]. Chem Eng News ,2010,88 (33) : 15-22.
5Buller HR,Lensing AW,Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis : the Einstein-DVT Dose-Ranging Study [ J ]. Blood, 2008, 112 ( 6 ) .. 2242 -2247.
6Lassen MR, Raskob GE, Gallus A. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2):a randomised double-blind trial[ Jl. Lancet,2010,375 (9717) : 807-815.
7Michael RL, Alexander G, Gary ER, et al. Apixaban versus Enoxaparin for ThromboprophyIaxis after Hip Replacement[ J ]. The New England Journal of Medicine, 2010,12 ( 363 ) : 2487 -2498.
8Harenberg J, Jorg I, Vukojevic Y, et al. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism:observations from the van Gogh trials [ J ]. Eur J Clin Pharmacol,2008,64(6) :555-563.
9Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition ) [ J ]. Chest,2008,133 (6 Suppl) :454S-545 S.
